CoChat
Sign Up
Cited by 27Multiple Sclerosis Research StudiesNerve injury and regenerationSpinal Cord Injury Research

The relevance of BDNF for neuroprotection and neuroplasticity in multiple sclerosis

Open access
Maiworm, Michelle·2024·Frontiers in Neurology
DOI 10.3389/fneur.2024.1385042PMC PMC11325594
Open this paper in CoChat — free accountOpen PDF

Abstract

Background: Neuroplasticity as a mechanism to overcome central nervous system injury resulting from different neurological diseases has gained increasing attention in recent years. However, deficiency of these repair mechanisms leads to the accumulation of neuronal damage and therefore long-term disability. To date, the mechanisms by which remyelination occurs and why the extent of remyelination differs interindividually between multiple sclerosis patients regardless of the disease course are unclear. A member of the neurotrophins family, the brain-derived neurotrophic factor (BDNF) has received particular attention in this context as it is thought to play a central role in remyelination and thus neuroplasticity, neuroprotection, and memory. Objective: To analyse the current literature regarding BDNF in different areas of multiple sclerosis and to provide an overview of the current state of knowledge in this field. Conclusion: To date, studies assessing the role of BDNF in patients with multiple sclerosis remain inconclusive. However, there is emerging evidence for a beneficial effect of BDNF in multiple sclerosis, as studies reporting positive effects on clinical as well as MRI characteristics outweighed studies assuming detrimental effects of BDNF. Furthermore, studies regarding the Val66Met polymorphism have not conclusively determined whether this is a protective or harmful factor in multiple sclerosis, but again most studies hypothesized a protective effect through modulation of BDNF secretion and anti-inflammatory effects with different effects in healthy controls and patients with multiple sclerosis, possibly due to the pro-inflammatory milieu in patients with multiple sclerosis. Further studies with larger cohorts and longitudinal follow-ups are needed to improve our understanding of the effects of BDNF in the central nervous system, especially in the context of multiple sclerosis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fneur.2024.1385042

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • mTORC1 plays a critical role in local synaptic protein synthesis and cytoskeletal reorganization, such as actin polymerization, enabling formation and stabilization of new synaptic connections.

    “mTORC1 plays a critical role in local synaptic protein synthesis and cytoskeletal reorganization, such as actin polymerization, enabling the formation and stabilization of new synaptic connections [90,91].”

    From Variations in BDNF and Their Role in the Neurotrophic Antidepressant Mechanisms of Ketamine and Esketamine: A Review (2024) · cites this paper as [91]

    The Introduction’s “BDNF signaling pathways” section says mTORC1 induces translation of proteins related to synaptic formation and promotes outgrowth of cytoskeletal filaments and dendritic spines. It does not specify local synaptic synthesis or actin polymerization, or directly attribute stabilization of new synaptic connections to mTORC1. No page number is available in our copy. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 163

  1. [1]Zivadinov R Weinstock-Guttman B Benedict R Tamaño-Blanco M Hussein S Abdelrahman N. Preservation of gray matter volume in multiple sclerosis patients with the met allele of the rs6265 (Val66Met) SNP of brain-derived neurotrophic factor. Hum Mol Genet. (2007) 16: 2659– 68. doi: 10.1093/hmg/ddm189 17656372 · DOI
  2. [2]KhorshidAhmad T Acosta C Cortes C Lakowski TM Gangadaran S Namaka M. Transcriptional regulation of brain-derived neurotrophic factor (BDNF) by methyl CpG binding protein 2 (MeCP2): a novel mechanism for re-myelination and/or myelin repair involved in the treatment of multiple sclerosis (MS). Mol Neurobiol. (2016) 53: 1092– 107. doi: 10.1007/s12035-014-9074-1 25579386 · DOI
  3. [3]Chao MV. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci. (2003) 4: 299– 309. doi: 10.1038/nrn1078 12671646 · DOI · Paper page
  4. [4]Chao MV Rajagopal R Lee FS. Neurotrophin signalling in health and disease. Clin Sci (Lond). (2006) 110: 167– 73. doi: 10.1042/CS20050163 16411893 · DOI
  5. [6]Xu B Gottschalk W Chow A Wilson RI Schnell E Zang K. The role of brain-derived neurotrophic factor receptors in the mature hippocampus: modulation of long-term potentiation through a presynaptic mechanism involving TrkB. J Neurosci. (2000) 20: 6888– 97. doi: 10.1523/JNEUROSCI.20-18-06888.2000 10995833 PMC2711895 · DOI
  6. [7]Yang H Feng G-D Liang Z Vitale A Jiao X-Y Ju G. In vitro beneficial activation of microglial cells by mechanically-injured astrocytes enhances the synthesis and secretion of BDNF through p38MAPK. Neurochem Int. (2012) 61: 175– 86. doi: 10.1016/j.neuint.2012.04.020 22561407 · DOI
  7. [8]Asami T Ito T Fukumitsu H Nomoto H Furukawa Y Furukawa S. Autocrine activation of cultured macrophages by brain-derived neurotrophic factor. Biochem Biophys Res Commun. (2006) 344: 941– 7. doi: 10.1016/j.bbrc.2006.03.228 16631618 · DOI
  8. [9]Charlton T Prowse N McFee A Heiratifar N Fortin T Paquette C. Brain-derived neurotrophic factor (BDNF) has direct anti-inflammatory effects on microglia. Front Cell Neurosci. (2023) 17: 1188672. doi: 10.3389/fncel.2023.1188672, PMID: 37404293 PMC10315457 · DOI
  9. [10]Miao H Li R Han C Lu X Zhang H. Minocycline promotes posthemorrhagic neurogenesis via M2 microglia polarization via upregulation of the TrkB/BDNF pathway in rats. J Neurophysiol. (2018) 120: 1307– 17. doi: 10.1152/jn.00234.2018 29790836 · DOI
  10. [12]Yu H-C Huang H-B Tseng H Hsien-Yu A Lu M-C. Brain-derived neurotrophic factor suppressed proinflammatory cytokines secretion and enhanced MicroRNA(miR)-3168 expression in macrophages. Int J Mol Sci. (2022) 23: 570. doi: 10.3390/ijms23010570 35009001 PMC8745218 · DOI
  11. [13]Stadelmann C Kerschensteiner M Misgeld T Brück W Hohlfeld R Lassmann H. BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain. (2002) 125: 75– 85. doi: 10.1093/brain/awf015 11834594 · DOI
  12. [14]Ksiazek-Winiarek DJ Szpakowski P Glabinski A. Neural plasticity in multiple sclerosis: the functional and molecular background. Neural Plast. (2015) 2015: 307175. doi: 10.1155/2015/307175 26229689 PMC4503575 · DOI
  13. [15]Shajarian M Alsahebfosoul F Etemadifar M. The effect of IFN-β treatment on plasma levels of BDNF and IL-6 in relapsing-remitting multiple sclerosis patients. Neuroimmunomodulation. (2021) 28: 150– 7. doi: 10.1159/000515595 34182566 · DOI
  14. [16]Yamamoto H Gurney ME. Human platelets contain brain-derived neurotrophic factor. J Neurosci. (1990) 10: 3469– 78. doi: 10.1523/JNEUROSCI.10-11-03469.1990 2230938 PMC6570101 · DOI
  15. [17]Cefis M Chaney R Quirié A Santini C Marie C Garnier P. Endothelial cells are an important source of BDNF in rat skeletal muscle. Sci Rep. (2022) 12: 311. doi: 10.1038/s41598-021-03740-8, PMID: 35013359 PMC8748777 · DOI
  16. [18]Guo S Kim W Lok J Lee S-R Besancon E Luo B-H. Neuroprotection via matrix-trophic coupling between cerebral endothelial cells and neurons. Proc Natl Acad Sci USA. (2008) 105: 7582– 7. doi: 10.1073/pnas.0801105105, PMID: 18495934 PMC2396701 · DOI · Paper page
  17. [19]Leventhal C Rafii S Rafii D Shahar A Goldman SA. Endothelial trophic support of neuronal production and recruitment from the adult mammalian subependyma. Mol Cell Neurosci. (1999) 13: 450– 64. doi: 10.1006/mcne.1999.0762 10383830 · DOI
  18. [20]Bayas A Hummel V Kallmann BA Karch C Toyka KV Rieckmann P. Human cerebral endothelial cells are a potential source for bioactive BDNF. Cytokine. (2002) 19: 55– 8. doi: 10.1006/cyto.2002.0892 12182839 · DOI
  19. [21]Fresegna D Bullitta S Musella A Rizzo F de Vito F Guadalupi L. Re-examining the role of TNF in MS pathogenesis and therapy. Cells. (2020) 9: e2290. doi: 10.3390/cells9102290, PMID: 33066433 PMC7602209 · DOI
  20. [22]Brum C Stertz L Borba E Rumi D Kapczinski F Camozzato A. Association of serum brain-derived neurotrophic factor (BDNF) and tumor necrosis factor-alpha (TNF-α) with diagnosis of delirium in oncology inpatients. Revista brasileira de psiquiatria. (2015) 37: 197– 202. doi: 10.1590/1516-4446-2014-1450 26376051 · DOI
  21. [23]Saha RN Liu X Pahan K. Up-regulation of BDNF in astrocytes by TNF-alpha: a case for the neuroprotective role of cytokine. J. Neuroimmune Pharmacol. (2006) 1: 212– 22. doi: 10.1007/s11481-006-9020-8 18040799 PMC2131740 · DOI
  22. [24]Rowhani-Rad Soodeh Taherianfard M. (2019): Crosstalk between BDNF and TNFα in brain versus serum of the cuprizone-induced multiple sclerosis in C57BL/6 mice. Physiology and Pharmacology. Online verfügbar unter, Available at: https://www.semanticscholar.org/paper/Crosstalk-between-BDNF-and-TNF%CE%B1-in-brain-versus-of-Rowhani-Rad-Taherianfard/31d392be49773c998d1d1d2bdf1ede062c982c20
  23. [25]Bałkowiec-Iskra E Vermehren-Schmaedick A Balkowiec A. Tumor necrosis factor-α increases brain-derived neurotrophic factor expression in trigeminal ganglion neurons in an activity-dependent manner. Neuroscience. (2011) 180: 322– 33. doi: 10.1016/j.neuroscience.2011.02.028 21335064 PMC3070813 · DOI
  24. [26]Marosi K Mattson MP. BDNF mediates adaptive brain and body responses to energetic challenges. Trends Endocrinol Metab. (2014) 25: 89– 98. doi: 10.1016/j.tem.2013.10.006 24361004 PMC3915771 · DOI · Paper page
  25. [28]Casaccia-Bonnefil P Gu C Khursigara G Chao MV. p75 neurotrophin receptor as a modulator of survival and death decisions. Microsc Res Tech. (1999) 45: 217– 24. doi: 10.1002/(SICI)1097-0029(19990515/01)45:4/5<217::AID-JEMT5>3.0.CO;2-5 10383114 · DOI
  26. [29]Ma D Zhang H Yin L Xu H Wu L Shaji R. Human iPSC-derived endothelial cells promote CNS remyelination via BDNF and mTORC1 pathway. Glia. (2024) 72: 133– 55. doi: 10.1002/glia.24466 37675625 · DOI
  27. [30]Chen A Xiong L-J Tong Y Mao M. Neuroprotective effect of brain-derived neurotrophic factor mediated by autophagy through the PI3K/Akt/mTOR pathway. Mol Med Rep. (2013) 8: 1011– 6. doi: 10.3892/mmr.2013.1628 23942837 · DOI
  28. [31]An X Yao X Li B Yang W Cui R Zhao G. Role of BDNF-mTORC1 Signaling pathway in female depression. Neural Plast. (2021) 2021: 6619515. doi: 10.1155/2021/6619515 33628219 PMC7886502 · DOI
  29. [32]Zhao T Qi Y Li Y Xu K. PI3 kinase regulation of neural regeneration and muscle hypertrophy after spinal cord injury. Mol Biol Rep. (2012) 39: 3541– 7. doi: 10.1007/s11033-011-1127-1 21720761 · DOI
  30. [33]Akram R Anwar H Javed M Rasul A Imran A Malik SA. Axonal regeneration: underlying molecular mechanisms and potential therapeutic targets. Biomedicines. (2022) 10: 123186. doi: 10.3390/biomedicines10123186, PMID: 36551942 PMC9775075 · DOI
  31. [34]Wong AW Xiao J Kemper D Kilpatrick TJ Murray SS. Oligodendroglial expression of TrkB independently regulates myelination and progenitor cell proliferation. J Neurosci. (2013) 33: 4947– 57. doi: 10.1523/JNEUROSCI.3990-12.2013 23486965 PMC6619007 · DOI
  32. [35]Cheng A Wan R Yang J-L Kamimura N Son T Ouyang X. Involvement of PGC-1α in the formation and maintenance of neuronal dendritic spines. Nat Commun. (2012) 3: 1250. doi: 10.1038/ncomms2238, PMID: 23212379 PMC4091730 · DOI · Paper page
  33. [36]Prokopova B Hlavacova N Vlcek M Penesova A Grunnerova L Garafova A. Early cognitive impairment along with decreased stress-induced BDNF in male and female patients with newly diagnosed multiple sclerosis. J Neuroimmunol. (2017) 302: 34– 40. doi: 10.1016/j.jneuroim.2016.11.007 27979325 · DOI
  34. [37]Sarchielli P Greco L Stipa A Floridi A Gallai V. Brain-derived neurotrophic factor in patients with multiple sclerosis. J Neuroimmunol. (2002) 132: 180– 8. doi: 10.1016/s0165-5728(02)00319-3 12417449 · DOI
  35. [38]Azoulay D Mausner-Fainberg K Urshansky N Fahoum F Karni A. Interferon-beta therapy up-regulates BDNF secretion from PBMCs of MS patients through a CD40-dependent mechanism. J Neuroimmunol. (2009) 211: 114– 9. doi: 10.1016/j.jneuroim.2009.04.004 19419774 · DOI
  36. [39]Azoulay D Vachapova V Shihman B Miler A Karni A. Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate. J Neuroimmunol. (2005) 167: 215– 8. doi: 10.1016/j.jneuroim.2005.07.001 16083971 · DOI
  37. [40]Frota ER Rodrigues DH Donadi EA Brum DG Maciel DRK Teixeira AL. Increased plasma levels of brain derived neurotrophic factor (BDNF) after multiple sclerosis relapse. Neurosci Lett. (2009) 460: 130– 2. doi: 10.1016/j.neulet.2009.05.057, PMID: 19477225 · DOI
  38. [41]Lalive PH Kantengwa S Benkhoucha M Juillard C Chofflon M. Interferon-beta induces brain-derived neurotrophic factor in peripheral blood mononuclear cells of multiple sclerosis patients. J Neuroimmunol. (2008) 197: 147– 51. doi: 10.1016/j.jneuroim.2008.04.033 18555540 · DOI
  39. [42]Lindquist S Hassinger S Lindquist JA Sailer M. The balance of pro-inflammatory and trophic factors in multiple sclerosis patients: effects of acute relapse and immunomodulatory treatment. Multiple Sclerosis. (2011) 17: 851– 66. doi: 10.1177/1352458511399797 21561957 · DOI
  40. [43]Caggiula M Batocchi A Frisullo G Angelucci F Patanella AK Sancricca C. Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy. Clin. Immunol. (2006) 118: 77– 82. doi: 10.1016/j.clim.2005.09.005, PMID: 16275091 · DOI
  41. [44]Gielen A Khademi M Muhallab S Olsson T Piehl F. Increased brain-derived neurotrophic factor expression in white blood cells of relapsing-remitting multiple sclerosis patients. Scand J Immunol. (2003) 57: 493– 7. doi: 10.1046/j.1365-3083.2003.01260.x 12753507 · DOI
  42. [45]Liguori M Fera F Patitucci A Manna I Condino F Valentino P. A longitudinal observation of brain-derived neurotrophic factor mRNA levels in patients with relapsing-remitting multiple sclerosis. Brain Res. (2009) 1256: 123– 8. doi: 10.1016/j.brainres.2008.11.047 19071096 · DOI
  43. [46]Sarchielli P Zaffaroni M Floridi A Greco L Candeliere A Mattioni A. Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins. Multiple Sclerosis. (2007) 13: 313– 31. doi: 10.1177/1352458506070146 17439900 · DOI
  44. [47]Damasceno A Damasceno B Cendes F Damasceno A Moraes AS Farias A. Serum BDNF levels are not reliable correlates of neurodegeneration in MS patients. Mult Scler Relat Disord. (2015) 4: 65– 6. doi: 10.1016/j.msard.2014.11.003 25787056 · DOI
  45. [48]Naegelin Y Saeuberli K Schaedelin S Dingsdale H Magon S Baranzini S. Levels of brain-derived neurotrophic factor in patients with multiple sclerosis. Ann. Clin. Trans. Neurol. (2020) 7: 2251– 61. doi: 10.1002/acn3.51215 PMC7664260 33031634 · DOI
  46. [49]Liguori M Fera F Gioia MC Valentino P Manna I Condino F. Investigating the role of brain-derived neurotrophic factor in relapsing-remitting multiple sclerosis. Genes Brain Behav. (2007) 6: 177– 83. doi: 10.1111/j.1601-183X.2006.00245.x 16740142 · DOI
  47. [50]Vacaras V Major ZZ Muresanu DF Krausz TL Marginean I Buzoianu DA. Effect of glatiramer acetate on peripheral blood brain-derived neurotrophic factor and phosphorylated TrkB levels in relapsing-remitting multiple sclerosis. CNS Neurol Disord Drug Targets. (2014) 13: 647– 51. doi: 10.2174/1871527313666140618110049 24938775 · DOI
  48. [51]Mehrpour M Akhoundi FH Delgosha M Keyvani H Motamed MR Sheibani B. Increased serum brain-derived neurotrophic factor in multiple sclerosis patients on interferon-β and its impact on functional abilities. Neurologist. (2015) 20: 57– 60. doi: 10.1097/NRL.0000000000000053 26468869 · DOI
  49. [52]Weinstock-Guttman B Zivadinov R Tamaño-Blanco M Abdelrahman N Badgett D Durfee J. Immune cell BDNF secretion is associated with white matter volume in multiple sclerosis. J Neuroimmunol. (2007) 188: 167– 74. doi: 10.1016/j.jneuroim.2007.06.003 17602759 · DOI
  50. [53]Maisonpierre PC le Beau MM Espinosa R Ip NY Belluscio L de la Monte SM. Human and rat brain-derived neurotrophic factor and neurotrophin-3: gene structures, distributions, and chromosomal localizations. Genomics. (1991) 10: 558– 68. doi: 10.1016/0888-7543(91)90436-i, PMID: 1889806 · DOI
  51. [54]Shen T You Y Joseph C Mirzaei M Klistorner A Graham SL. BDNF polymorphism: a review of its diagnostic and clinical relevance in neurodegenerative disorders. Aging Dis. (2018) 9: 523– 36. doi: 10.14336/AD.2017.0717 29896439 PMC5988606 · DOI
  52. [55]Egan MF Kojima M Callicott JH Goldberg TE Kolachana BS Bertolino A. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. (2003) 112: 257– 69. doi: 10.1016/s0092-8674(03)00035-7 12553913 · DOI · Paper page
  53. [56]Chiaruttini C Vicario A Li Z Baj G Braiuca P Wu Y. Dendritic trafficking of BDNF mRNA is mediated by translin and blocked by the G196A (Val66Met) mutation. Proc Natl Acad Sci USA. (2009) 106: 16481– 6. doi: 10.1073/pnas.0902833106 19805324 PMC2752540 · DOI · Paper page
  54. [57]Chen Z-Y Patel PD Sant G Meng C-X Teng KK Hempstead BL. Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. J Neurosci. (2004) 24: 4401– 11. doi: 10.1523/JNEUROSCI.0348-04.2004 15128854 PMC6729450 · DOI · Paper page
  55. [58]Dinacci D Tessitore A Russo A de Bonis ML Lavorgna L Picconi O. BDNF Val66Met polymorphism and brain volumes in multiple sclerosis. Neurol. Sci. (2011) 32: 117– 23. doi: 10.1007/s10072-010-0433-z, PMID: 20953813 · DOI
  56. [59]Hamamcioglu K Reder AT. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England). (2007) 13: 459– 70. doi: 10.1177/1352458506069672 17463069 · DOI
  57. [60]Ramasamy DP Ramanathan M Cox JL Antulov R Weinstock-Guttman B Bergsland N. Effect of Met66 allele of the BDNF rs6265 SNP on regional gray matter volumes in patients with multiple sclerosis: a voxel-based morphometry study. Pathophysiology. (2011) 18: 53– 60. doi: 10.1016/j.pathophys.2010.04.006 20478698 · DOI
  58. [61]Chen Z-Y Jing D Bath KG Ieraci A Khan T Siao C-J. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science. (2006) 314: 140– 3. doi: 10.1126/science.1129663 17023662 PMC1880880 · DOI · Paper page
  59. [62]Lang UE Hellweg R Sander T Gallinat J. The met allele of the BDNF Val66Met polymorphism is associated with increased BDNF serum concentrations. Mol Psychiatry. (2009) 14: 120– 2. doi: 10.1038/mp.2008.80 19156154 · DOI
  60. [63]Minelli A Zanardini R Bonvicini C Sartori R Pedrini L Gennarelli M. BDNF serum levels, but not BDNF Val66Met genotype, are correlated with personality traits in healthy subjects. Eur Arch Psychiatry Clin Neurosci. (2011) 261: 323– 9. doi: 10.1007/s00406-011-0189-3 21290143 · DOI
  61. [64]Ozan E Okur H Eker C Eker OD Gönül A Akarsu N. The effect of depression, BDNF gene val66met polymorphism and gender on serum BDNF levels. Brain Res Bull. (2010) 81: 61– 5. doi: 10.1016/j.brainresbull.2009.06.022 19589373 · DOI
  62. [65]Yoshimura R Kishi T Suzuki A Umene-Nakano W Ikenouchi-Sugita A Hori H. The brain-derived neurotrophic factor (BDNF) polymorphism Val66Met is associated with neither serum BDNF level nor response to selective serotonin reuptake inhibitors in depressed Japanese patients. Prog Neuro-Psychopharmacol Biol Psychiatry. (2011) 35: 1022– 5. doi: 10.1016/j.pnpbp.2011.02.009 21338649 · DOI
  63. [66]Zhou Z Lu T Xu G Yue X Zhu W Ma M. Decreased serum brain-derived neurotrophic factor (BDNF) is associated with post-stroke depression but not with BDNF gene Val66Met polymorphism. Clin Chem Lab Med. (2011) 49: 185– 9. doi: 10.1515/CCLM.2011.039 21143020 · DOI
  64. [67]Hashimoto T Lewis DA. BDNF Val66Met polymorphism and GAD67 mRNA expression in the prefrontal cortex of subjects with schizophrenia. Am J Psychiatry. (2006) 163: 534– 7. doi: 10.1176/appi.ajp.163.3.534 16513879 · DOI
  65. [68]Tramontina J Frey BN Andreazza AC Zandona M Santin A Kapczinski F. Val66met polymorphism and serum brain-derived neurotrophic factor levels in bipolar disorder. Mol Psychiatry. (2007) 12: 230– 1. doi: 10.1038/sj.mp.4001941 17325716 · DOI
  66. [69]Amidfar M de Oliveira J Kucharska E Budni J Kim Y-K. The role of CREB and BDNF in neurobiology and treatment of Alzheimer’s disease. Life Sci. (2020) 257: 118020. doi: 10.1016/j.lfs.2020.118020, PMID: 32603820 · DOI
  67. [70]Islam O Loo TX Heese K. Brain-derived neurotrophic factor (BDNF) has proliferative effects on neural stem cells through the truncated TRK-B receptor, MAP kinase, AKT, and STAT-3 signaling pathways. Curr Neurovasc Res. (2009) 6: 42– 53. doi: 10.2174/156720209787466028 19355925 · DOI
  68. [71]Leal G. Bramham C. R. Duarte C. B. (2017): Chapter 8—BDNF and hippocampal synaptic plasticity. Litwack Gerald (Ed.), Vitamins and hormones: Neurotrophins, Academic Press, 153– 195 28215294
  69. [72]Seidler K Barrow M. Intermittent fasting and cognitive performance - targeting BDNF as potential strategy to optimise brain health. Front Neuroendocrinol. (2022) 65: 100971. doi: 10.1016/j.yfrne.2021.100971 34929259 · DOI
  70. [73]Loprinzi PD. Does brain-derived neurotrophic factor mediate the effects of exercise on memory? Phys Sportsmed. (2019) 47: 395– 405. doi: 10.1080/00913847.2019.1610255 31002004 · DOI
  71. [74]Dincheva I Lynch NB Lee FS. The role of BDNF in the development of fear learning. Depress Anxiety. (2016) 33: 907– 16. doi: 10.1002/da.22497 27699937 PMC5089164 · DOI
  72. [76]Vigers AJ Amin DS Talley-Farnham T Gorski JA Xu B Jones KR. Sustained expression of brain-derived neurotrophic factor is required for maintenance of dendritic spines and normal behavior. Neuroscience. (2012) 212: 1– 18. doi: 10.1016/j.neuroscience.2012.03.031 22542678 PMC4880414 · DOI · Paper page
  73. [77]Patanella AK Zinno M Quaranta D Nociti V Frisullo G Gainotti G. Correlations between peripheral blood mononuclear cell production of BDNF, TNF-alpha, IL-6, IL-10 and cognitive performances in multiple sclerosis patients. J Neurosci Res. (2010) 88: 1106– 12. doi: 10.1002/jnr.22276 19885866 · DOI
  74. [78]Hulst HE Schoonheim MM Roosendaal SD Popescu V Schweren LJS van der Werf YD. Functional adaptive changes within the hippocampal memory system of patients with multiple sclerosis. Hum Brain Mapp. (2012) 33: 2268– 80. doi: 10.1002/hbm.21359 21898674 PMC6869948 · DOI
  75. [79]Kern KC Ekstrom AD Suthana NA Giesser BS Montag M Arshanapalli A. Fornix damage limits verbal memory functional compensation in multiple sclerosis. NeuroImage. (2012) 59: 2932– 40. doi: 10.1016/j.neuroimage.2011.09.071 22001266 · DOI
  76. [80]Greenberg ME Xu B Lu B Hempstead BL. New insights in the biology of BDNF synthesis and release: implications in CNS function. J Neurosci. (2009) 29: 12764– 7. doi: 10.1523/JNEUROSCI.3566-09.2009 19828787 PMC3091387 · DOI · Paper page
  77. [81]Hariri AR Goldberg TE Mattay VS Kolachana BS Callicott JH Egan MF. Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci. (2003) 23: 6690– 4. doi: 10.1523/JNEUROSCI.23-17-06690.2003 12890761 PMC6740735 · DOI · Paper page
  78. [82]Lu B. BDNF and activity-dependent synaptic modulation. Learn Memory. (2003) 10: 86– 98. doi: 10.1101/lm.54603 PMC5479144 12663747 · DOI · Paper page
  79. [83]Ninan I Bath KG Dagar K Perez-Castro R Plummer MR. The BDNF Val66Met polymorphism impairs NMDA receptor-dependent synaptic plasticity in the hippocampus. J Neurosci. (2010) 30: 8866– 70. doi: 10.1523/JNEUROSCI.1405-10.2010 20592208 PMC2911131 · DOI · Paper page
  80. [84]Castrén E Pitkänen M Sirviö J Parsadanian A Lindholm D Thoenen H. The induction of LTP increases BDNF and NGF mRNA but decreases NT-3 mRNA in the dentate gyrus. Neuroreport. (1993) 4: 895– 8. doi: 10.1097/00001756-199307000-00014 8396461 · DOI · Paper page
  81. [85]Falkenberg T Mohammed AK Henriksson B Persson H Winblad B Lindefors N. Increased expression of brain-derived neurotrophic factor mRNA in rat hippocampus is associated with improved spatial memory and enriched environment. Neurosci Lett. (1992) 138: 153– 6. doi: 10.1016/0304-3940(92)90494-r 1407655 · DOI
  82. [86]Yalachkov Y Anschütz V Maiworm M Jakob J Schaller-Paule MA Schäfer JH. Serum and cerebrospinal fluid BDNF concentrations are associated with neurological and cognitive improvement in multiple sclerosis: a pilot study. Mult Scler Relat Disord. (2023) 71: 104567. doi: 10.1016/j.msard.2023.104567 36805176 · DOI
  83. [87]Engin E. Żarnowska E. Sigal M. Keist R. Zeller A. Pearce R., (2013): Alpha5-containing GABAA receptors in dentate gyrus enable cognitive flexibility. FASEB J. Online verfügbar unter, Available at: https://www.semanticscholar.org/paper/Alpha5%E2%80%90containing-GABAA-receptors-in-dentate-gyrus-Engin-%C5%BBarnowska/2ee0614f381d68b821e698e92403e16659a7ead6
  84. [88]Håkansson K Ledreux A Daffner K Terjestam Y Bergman P Carlsson R. BDNF responses in healthy older persons to 35 minutes of physical exercise, cognitive training, and mindfulness: associations with working memory function. J Alzheimer’s Disease. (2017) 55: 645– 57. doi: 10.3233/JAD-160593 27716670 PMC6135088 · DOI
  85. [89]Song J-H Yu J-T Tan L. Brain-derived neurotrophic factor in Alzheimer’s disease: risk, mechanisms, and therapy. Mol Neurobiol. (2015) 52: 1477– 93. doi: 10.1007/s12035-014-8958-4 25354497 · DOI
  86. [90]Giordano A Clarelli F Cannizzaro M Mascia E Santoro S Sorosina M. BDNF Val66Met polymorphism is associated with motor recovery after rehabilitation in progressive multiple sclerosis patients. Front Neurol. (2022) 13: 790360. doi: 10.3389/fneur.2022.790360 35265024 PMC8899087 · DOI
  87. [91]Cerasa A Tongiorgi E Fera F Gioia MC Valentino P Liguori M. The effects of BDNF Val66Met polymorphism on brain function in controls and patients with multiple sclerosis: an imaging genetic study. Behav Brain Res. (2010) 207: 377– 86. doi: 10.1016/j.bbr.2009.10.022 19874854 · DOI
  88. [92]Fera F Passamonti L Cerasa A Gioia M Liguori M Manna I. The BDNF Val66Met polymorphism has opposite effects on memory circuits of multiple sclerosis patients and controls. PLoS One. (2013) 8: e61063. doi: 10.1371/journal.pone.0061063, PMID: 23593393 PMC3623818 · DOI
  89. [93]Kambeitz JP Bhattacharyya S Kambeitz-Ilankovic LM Valli I Collier DA McGuire P. Effect of BDNF val(66)met polymorphism on declarative memory and its neural substrate: a meta-analysis. Neurosci Biobehav Rev. (2012) 36: 2165– 77. doi: 10.1016/j.neubiorev.2012.07.002 22813992 · DOI
  90. [94]Mero I-L Smestad C Lie BA Lorentzen ÅR Sandvik L Landrø NI. Polymorphisms of the BDNF gene show neither association with multiple sclerosis susceptibility nor clinical course. J Neuroimmunol. (2012) 244: 107– 10. doi: 10.1016/j.jneuroim.2012.01.011 22341604 · DOI
  91. [95]Ehling R di Pauli F Lackner P Rainer C Kraus V Hegen H. Impact of glatiramer acetate on paraclinical markers of neuroprotection in multiple sclerosis: a prospective observational clinical trial. J Neuroimmunol. (2015) 287: 98– 105. doi: 10.1016/j.jneuroim.2015.08.004, PMID: 26439969 · DOI
  92. [96]Islas-Hernandez A Aguilar-Talamantes H Bertado-Cortes B Mejia-delCastillo G d J Carrera-Pineda R Cuevas-Garcia CF. BDNF and tau as biomarkers of severity in multiple sclerosis. Biomark Med. (2018) 12: 717– 26. doi: 10.2217/bmm-2017-0374, PMID: 29865854 · DOI
  93. [97]Lindquist S Schott BH Ban M Compston DAS Sawcer S Sailer M. The BDNF-Val66Met polymorphism: implications for susceptibility to multiple sclerosis and severity of disease. J Neuroimmunol. (2005) 167: 183– 5. doi: 10.1016/j.jneuroim.2005.06.008 16046000 · DOI
  94. [98]Blanco Y Gómez-Choco M Arostegui JL Casanova B Martínez-Rodríguez JE Boscá I. No association of the Val66Met polymorphism of brain-derived neurotrophic factor (BDNF) to multiple sclerosis. Neurosci Lett. (2006a) 396: 217– 9. doi: 10.1016/j.neulet.2005.11.032 16356643 · DOI
  95. [99]Nociti V Santoro M Quaranta D Losavio F de Fino C Giordano R. BDNF rs6265 polymorphism methylation in multiple sclerosis: a possible marker of disease progression. PLoS One. (2018) 13: e0206140. doi: 10.1371/journal.pone.0206140, PMID: 30352103 PMC6198951 · DOI
  96. [100]Portaccio E Bellinvia A Prestipino E Nacmias B Bagnoli S Razzolini L. The brain-derived neurotrophic factor Val66Met polymorphism can protect against cognitive impairment in multiple sclerosis. Front Neurol. (2021) 12: 645220. doi: 10.3389/fneur.2021.645220 33815257 PMC8011315 · DOI
  97. [101]Mirowska-Guzel D Mach A Gromadzka G Czlonkowski A Czlonkowska A. BDNF A196G and C270T gene polymorphisms and susceptibility to multiple sclerosis in the polish population. Gender differences. J Neuroimmunol. (2008) 193: 170. doi: 10.1016/j.jneuroim.2007.10.013 18061279 · DOI
  98. [102]Comini-Frota ER Rodrigues DH Miranda EC Brum DG Kaimen-Maciel DR Donadi EA. Serum levels of brain-derived neurotrophic factor correlate with the number of T2 MRI lesions in multiple sclerosis. Braz. J. Med. Biol. Res. (2012) 45: 68– 71. doi: 10.1590/s0100-879x2011007500165 22183248 PMC3854145 · DOI
  99. [103]Brod SA Lincoln JA Nelson F. Myelinating proteins in MS are linked to volumetric brain MRI changes. J. Neuroimaging. (2019) 29: 400– 5. doi: 10.1111/jon.12605 30748043 · DOI
  100. [105]Zachary C Gorski JA Jones KR. Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. J Neurosci. (2004) 24: 4250– 8. doi: 10.1523/JNEUROSCI.3920-03.2004 15115821 PMC6729276 · DOI · Paper page
  101. [106]Charil A Dagher A Lerch JP Zijdenbos AP Worsley KJ Evans AC. Focal cortical atrophy in multiple sclerosis: relation to lesion load and disability. NeuroImage. (2007) 34: e6. doi: 10.1016/j.neuroimage.2006.10.006 17112743 · DOI
  102. [107]Prinster A Quarantelli M Orefice G Lanzillo R Brunetti A Mollica C. Grey matter loss in relapsing–remitting multiple sclerosis: a voxel-based morphometry study. NeuroImage. (2006) 29: 859– 67. doi: 10.1016/j.neuroimage.2005.08.034 16203159 · DOI
  103. [108]Dolcetti E Bruno A Azzolini F Gilio L Moscatelli A de Vito F. The BDNF Val66Met polymorphism (rs6265) modulates inflammation and neurodegeneration in the early phases of multiple sclerosis. Genes. (2022) 13. doi: 10.3390/genes13020332, PMID: 35205376 PMC8871843 · DOI
  104. [109]de Meo E Portaccio E Prestipino E Nacmias B Bagnoli S Razzolini L. Effect of BDNF Val66Met polymorphism on hippocampal subfields in multiple sclerosis patients. Mol Psychiatry. (2022) 27: 1010– 9. doi: 10.1038/s41380-021-01345-1, PMID: 34650209 · DOI
  105. [110]Blanco Y Moral EA Costa M Gómez-Choco M Torres-Peraza JF Alonso-Magdalena L. Effect of glatiramer acetate (Copaxone) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis: a longitudinal study. Neurosci Lett. (2006b) 406: 270– 5. doi: 10.1016/j.neulet.2006.07.043 16934924 · DOI
  106. [111]Chen M Valenzuela R Dhib-Jalbut S. Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor. J Neurol Sci. (2003) 215: 37– 44. doi: 10.1016/s0022-510x(03)00177-1, PMID: 14568126 · DOI
  107. [112]Ziemssen T Kümpfel T Schneider H Klinkert WEF Neuhaus O Hohlfeld R. Secretion of brain-derived neurotrophic factor by glatiramer acetate-reactive T-helper cell lines: implications for multiple sclerosis therapy. J Neurol Sci. (2005) 233: 109. doi: 10.1016/j.jns.2005.03.010 15869765 · DOI
  108. [113]Ruggieri M Avolio C Livrea P Trojano M. Glatiramer acetate in multiple sclerosis: a review. CNS Drug Rev. (2007) 13: 178– 91. doi: 10.1111/j.1527-3458.2007.00010.x 17627671 PMC6726353 · DOI
  109. [114]Arnon R Aharoni R. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc Natl Acad Sci USA. (2004) 101: 14593– 8. doi: 10.1073/pnas.0404887101 15371592 PMC521994 · DOI
  110. [116]Aharoni R Eilam R Domev H Labunskay G Sela M Arnon R. The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc Natl Acad Sci USA. (2005) 102: 19045– 50. doi: 10.1073/pnas.0509438102 16365293 PMC1323190 · DOI
  111. [117]Aharoni R Kayhan B Eilam R Sela M Arnon R. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc Natl Acad Sci USA. (2003) 100: 14157– 62. doi: 10.1073/pnas.2336171100 14614135 PMC283562 · DOI
  112. [118]Ziemssen T Kümpfel T Klinkert WEF Neuhaus O Hohlfeld R. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain. (2002) 125: 2381– 91. doi: 10.1093/brain/awf252 12390966 · DOI
  113. [119]Gilgun-Sherki Y Panet H Holdengreber V Mosberg-Galili R Offen D. Axonal damage is reduced following glatiramer acetate treatment in C57/bl mice with chronic-induced experimental autoimmune encephalomyelitis. Neurosci Res. (2003) 47: 201– 7. doi: 10.1016/s0168-0102(03)00217-7 14512144 · DOI
  114. [120]Lee D-H Geyer E Flach A-C Jung K Gold R Flügel A. Central nervous system rather than immune cell-derived BDNF mediates axonal protective effects early in autoimmune demyelination. Acta Neuropathol. (2012) 123: 247– 58. doi: 10.1007/s00401-011-0890-3 22009304 PMC3259380 · DOI
  115. [121]Golan M Mausner-Fainberg K Ibrahim B Benhamou M Wilf-Yarkoni A Kolb H. Fingolimod increases brain-derived neurotrophic factor level secretion from circulating T cells of patients with multiple sclerosis. CNS Drugs. (2019) 33: 1229– 37. doi: 10.1007/s40263-019-00675-7 31713782 · DOI
  116. [122]Petereit HF Lindemann H Schoppe S. Effect of immunomodulatory drugs on in vitro production of brain-derived neurotrophic factor. Multiple Sclerosis. (2003) 9: 16– 20. doi: 10.1191/1352458503ms869oa 12617262 · DOI
  117. [123]Kalinowska-Łyszczarz A Pawlak MA Wyciszkiewicz A Osztynowicz K Kozubski W Michalak S. Immune-cell BDNF expression in treatment-naïve relapsing-remitting multiple sclerosis patients and following one year of immunomodulation therapy. Neurol Neurochir Pol. (2018) 52: 483– 9. doi: 10.1016/j.pjnns.2018.03.006 29643001 · DOI
  118. [124]Smith PA Schmid C Zurbruegg S Jivkov M Doelemeyer A Theil D. Fingolimod inhibits brain atrophy and promotes brain-derived neurotrophic factor in an animal model of multiple sclerosis. J Neuroimmunol. (2018) 318: 103– 13. doi: 10.1016/j.jneuroim.2018.02.016 29530550 · DOI
  119. [125]Văcăraş V Major Z Buzoianu AD Zsigmond A Dana BA. Brain-derived neurotrophic factor levels under chronic natalizumab treatment in multiple sclerosis. A preliminary report. Neurol Neurochir Pol. (2017) 51: 221– 6. doi: 10.1016/j.pjnns.2017.03.002, PMID: 28392137 · DOI
  120. [126]Muraro PA Douek DC Packer A Chung K Guenaga FJ Cassiani-Ingoni R. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med. (2005) 201: 805– 16. doi: 10.1084/jem.20041679 15738052 PMC2212822 · DOI
  121. [127]Blanco Y Saiz A Costa M Torres-Peraza JF Carreras E Alberch J. Evolution of brain-derived neurotrophic factor levels after autologous hematopietic stem cell transplantation in multiple sclerosis. Neurosci Lett. (2005) 380: 122– 6. doi: 10.1016/j.neulet.2005.01.032 15854763 · DOI
  122. [128]Giedraitiene N Gasciauskaite G Kaubrys G. Impact of autologous HSCT on the quality of life and fatigue in patients with relapsing multiple sclerosis. Sci Rep. (2022) 12: 15404. doi: 10.1038/s41598-022-19748-7 36100664 PMC9470541 · DOI
  123. [129]Mancardi GL Sormani MP Di Gioia M Vuolo L Gualandi F Amato MP. Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-Centre experience. Multiple Sclerosis. (2012) 18: 835– 42. doi: 10.1177/1352458511429320 22127896 · DOI
  124. [130]Burt RK Balabanov R Burman J Sharrack B Snowden JA Oliveira MC. Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial. JAMA. (2019) 321: 165– 74. doi: 10.1001/jama.2018.18743 30644983 PMC6439765 · DOI
  125. [131]Dalgas U Langeskov-Christensen M Stenager E Riemenschneider M Hvid LG. Exercise as medicine in multiple sclerosis—time for a paradigm shift: preventive, symptomatic, and disease-modifying aspects and perspectives. Curr Neurol Neurosci Rep. (2019) 19: 88. doi: 10.1007/s11910-019-1002-3 31720862 · DOI
  126. [132]Begliuomini S Lenzi E Ninni F Casarosa E Merlini S Pluchino N. Plasma brain-derived neurotrophic factor daily variations in men: correlation with cortisol circadian rhythm. J Endocrinol. (2008) 197: 429– 35. doi: 10.1677/JOE-07-0376 18434373 · DOI
  127. [133]Lu Y Christian K Lu B. BDNF: a key regulator for protein synthesis-dependent LTP and long-term memory? Neurobiol Learn Mem. (2008) 89: 312– 23. doi: 10.1016/j.nlm.2007.08.018 17942328 PMC2387254 · DOI
  128. [134]Thoenen H. Neurotrophins and neuronal plasticity. Science. (1995) 270: 593– 8. doi: 10.1126/science.270.5236.593 7570017 · DOI · Paper page
  129. [135]Pedersen BK. Physical activity and muscle-brain crosstalk. Nat Rev Endocrinol. (2019) 15: 383– 92. doi: 10.1038/s41574-019-0174-x 30837717 · DOI · Paper page
  130. [137]Wrann CD White JP Salogiannnis J Laznik-Bogoslavski D Wu J Ma D. Exercise induces hippocampal BDNF through a PGC-1α/FNDC5 pathway. Cell Metab. (2013) 18: 649– 59. doi: 10.1016/j.cmet.2013.09.008 24120943 PMC3980968 · DOI · Paper page
  131. [138]Gentile A Musella A de Vito F Rizzo FR Fresegna D Bullitta S. Immunomodulatory effects of exercise in experimental multiple sclerosis. Front Immunol. (2019) 10: 2197. doi: 10.3389/fimmu.2019.02197, PMID: 31572399 PMC6753861 · DOI
  132. [139]Guo L Lozinski B Yong VW. Exercise in multiple sclerosis and its models: focus on the central nervous system outcomes. J Neurosci Res. (2020) 98: 509– 23. doi: 10.1002/jnr.24524, PMID: 31486115 · DOI
  133. [140]Vaynman S Ying Z Gomez-Pinilla F. The select action of hippocampal calcium calmodulin protein kinase II in mediating exercise-enhanced cognitive function. Neuroscience. (2007) 144: 825– 33. doi: 10.1016/j.neuroscience.2006.10.005 17161914 PMC2805704 · DOI
  134. [141]Jørgensen MLK Kjølhede T Dalgas U Hvid LG. Plasma brain-derived neurotrophic factor (BDNF) and sphingosine-1-phosphat (S1P) are NOT the main mediators of neuroprotection induced by resistance training in persons with multiple sclerosis-a randomized controlled trial. Mult Scler Relat Disord. (2019) 31: 106– 11. doi: 10.1016/j.msard.2019.03.029 30965275 · DOI
  135. [142]Abbaspoor E Zolfaghari M Ahmadi B Khodaei K. The effect of combined functional training on BDNF, IGF-1, and their association with health-related fitness in the multiple sclerosis women. J. Growth Hormone Res. Soc. Int. IGF Res. Soc. (2020) 52: 101320. doi: 10.1016/j.ghir.2020.101320 32305012 · DOI
  136. [143]Briken S Rosenkranz S Keminer O Patra S Ketels G Heesen C. Effects of exercise on Irisin, BDNF and IL-6 serum levels in patients with progressive multiple sclerosis. J Neuroimmunol. (2016) 299: 53– 8. doi: 10.1016/j.jneuroim.2016.08.007, PMID: 27725121 · DOI
  137. [144]Schulz K-H Gold SM Witte J Bartsch K Lang UE Hellweg R. Impact of aerobic training on immune-endocrine parameters, neurotrophic factors, quality of life and coordinative function in multiple sclerosis. J Neurol Sci. (2004) 225: 11– 8. doi: 10.1016/j.jns.2004.06.009 15465080 · DOI
  138. [145]Waschbisch A Wenny I Tallner A Schwab S Pfeifer K Mäurer M. Physical activity in multiple sclerosis: a comparative study of vitamin D, brain-derived neurotrophic factor and regulatory T cell populations. Eur Neurol. (2012) 68: 122– 8. doi: 10.1159/000337904 22832849 · DOI
  139. [147]Ozkul C Guclu-Gunduz A Irkec C Fidan I Aydin Y Ozkan T. Effect of combined exercise training on serum brain-derived neurotrophic factor, suppressors of cytokine signaling 1 and 3 in patients with multiple sclerosis. J Neuroimmunol. (2018) 316: 121– 9. doi: 10.1016/j.jneuroim.2018.01.002 29329698 · DOI
  140. [148]Banitalebi E Ghahfarrokhi M Negaresh R Kazemi A Faramarzi M Motl RW. Exercise improves neurotrophins in multiple sclerosis independent of disability status. Mult Scler Relat Disord. (2020) 43: 102143. doi: 10.1016/j.msard.2020.102143, PMID: 32473563 · DOI
  141. [149]Eftekhari E Etemadifar M. Interleukin-10 and brain-derived neurotrophic factor responses to the mat Pilates training in women with multiple sclerosis. Sci Med. (2018) 28: 31668. doi: 10.15448/1980-6108.2018.4.31668 · DOI
  142. [150]Khademosharie M Tadibi V Behpoor N Hamedinia MR. The effect of 12-weeks concurent training on the serum levels NGF, BDNF, and VDBP in women with multiple sclerosis (2018) 17: 77– 86. doi: 10.22631/ijaep.v7i1.228, · DOI
  143. [151]Mokhtarzade M Motl R Negaresh R Zimmer P Khodadoost M Baker JS. Exercise-induced changes in neurotrophic factors and markers of blood-brain barrier permeability are moderated by weight status in multiple sclerosis. Neuropeptides. (2018) 70: 93– 100. doi: 10.1016/j.npep.2018.05.010 29880392 · DOI
  144. [152]Savšek L Stergar T Strojnik V Ihan A Koren A Špiclin Ž. Impact of aerobic exercise on clinical and magnetic resonance imaging biomarkers in persons with multiple sclerosis: an exploratory randomized controlled trial. J Rehabil Med. (2021) 53: jrm00178. doi: 10.2340/16501977-2814, PMID: 33739437 PMC8814886 · DOI
  145. [153]Wens I Keytsman C Deckx N Cools N Dalgas U Eijnde BO. Brain derived neurotrophic factor in multiple sclerosis: effect of 24 weeks endurance and resistance training. Eur J Neurol. (2016) 23: 1028– 35. doi: 10.1111/ene.12976 26992038 · DOI
  146. [154]Diechmann MD Campbell E Coulter E Paul L Dalgas U Hvid LG. Effects of exercise training on neurotrophic factors and subsequent neuroprotection in persons with multiple sclerosis-a systematic review and meta-analysis. Brain Sci. (2021) 11: 111499. doi: 10.3390/brainsci11111499 PMC8615767 34827498 · DOI
  147. [155]Church DD Hoffman JR Mangine GT Jajtner AR Townsend JR Beyer KS. Comparison of high-intensity vs. high-volume resistance training on the BDNF response to exercise. J. Appl. Physiol. (2016) 121: 123– 8. doi: 10.1152/japplphysiol.00233.2016 27231312 · DOI
  148. [157]Dinoff A Herrmann N Swardfager W Liu CS Sherman C Chan S. The effect of exercise training on resting concentrations of peripheral brain-derived neurotrophic factor (BDNF): a meta-analysis. PLoS One. (2016) 11: e0163037. doi: 10.1371/journal.pone.0163037 27658238 PMC5033477 · DOI
  149. [158]Ferris LT Williams JS Shen C-L. The effect of acute exercise on serum brain-derived neurotrophic factor levels and cognitive function. Med Sci Sports Exerc. (2007) 39: 728– 34. doi: 10.1249/mss.0b013e31802f04c7 17414812 · DOI · Paper page
  150. [159]Lippi G Mattiuzzi C Sanchis-Gomar F. Updated overview on interplay between physical exercise, neurotrophins, and cognitive function in humans. J Sport Health Sci. (2020) 9: 74– 81. doi: 10.1016/j.jshs.2019.07.012 31921482 PMC6943756 · DOI
  151. [160]Reycraft JT Islam H Townsend LK Hayward GC Hazell TJ Macpherson REK. Exercise intensity and recovery on circulating brain-derived neurotrophic factor. Med Sci Sports Exerc. (2020) 52: 1210– 7. doi: 10.1249/MSS.0000000000002242 31815833 · DOI
  152. [161]Schmolesky MT Webb DL Hansen RA. The effects of aerobic exercise intensity and duration on levels of brain-derived neurotrophic factor in healthy men. J. Sports Sci. Med. (2013) 12: 502– 11. 24149158 PMC3772595
  153. [163]Zimmer P Bloch W Schenk A Oberste M Riedel S Kool J. High-intensity interval exercise improves cognitive performance and reduces matrix metalloproteinases-2 serum levels in persons with multiple sclerosis: a randomized controlled trial. Multiple Sclerosis. (2018) 24: 1635– 44. doi: 10.1177/1352458517728342 28825348 · DOI
  154. [164]El-Sayes J Harasym D Turco CV Locke MB Nelson AJ. Exercise-induced neuroplasticity: a mechanistic model and prospects for promoting plasticity. Neuroscientist. (2019) 25: 65– 85. doi: 10.1177/1073858418771538 29683026 · DOI
  155. [165]Bonfiglio T Olivero G Vergassola M Di Cesare Mannelli L Pacini A Iannuzzi F. Environmental training is beneficial to clinical symptoms and cortical presynaptic defects in mice suffering from experimental autoimmune encephalomyelitis. Neuropharmacology. (2019) 145: 75– 86. doi: 10.1016/j.neuropharm.2018.01.026 29402503 · DOI
  156. [166]Mandolesi G Bullitta S Fresegna D de Vito F Rizzo FR Musella A. Voluntary running wheel attenuates motor deterioration and brain damage in cuprizone-induced demyelination. Neurobiol Dis. (2019) 129: 102– 17. doi: 10.1016/j.nbd.2019.05.010, PMID: 31100354 · DOI
  157. [167]Souza PS Gonçalves ED Pedroso GS Farias HR Junqueira SC Marcon R. Physical exercise attenuates experimental autoimmune encephalomyelitis by inhibiting peripheral immune response and blood-brain barrier disruption. Mol Neurobiol. (2017) 54: 4723– 37. doi: 10.1007/s12035-016-0014-0 27447807 · DOI
  158. [168]Xie Y Li Z Wang Y Xue X Ma W Zhang Y. Effects of moderate- versus high- intensity swimming training on inflammatory and CD4+ T cell subset profiles in experimental autoimmune encephalomyelitis mice. J Neuroimmunol. (2019) 328: 60– 7. doi: 10.1016/j.jneuroim.2018.12.005 30583216 · DOI
  159. [169]Tsuchimine S Sugawara N Ishioka M Yasui-Furukori N. Preanalysis storage conditions influence the measurement of brain-derived neurotrophic factor levels in peripheral blood. Neuropsychobiology. (2014) 69: 83– 8. doi: 10.1159/000358061 24577046 · DOI
  160. [170]Gejl A Enevold C Bugge A Andersen MS Nielsen CH Andersen LB. Associations between serum and plasma brain-derived neurotrophic factor and influence of storage time and centrifugation strategy. Sci Rep. (2019) 9: 9655. doi: 10.1038/s41598-019-45976-5, PMID: 31273250 PMC6609657 · DOI
  161. [171]Wilson DH Rissin DM Kan CW Fournier DR Piech T Campbell TG. The Simoa HD-1 analyzer: a novel fully automated digital immunoassay analyzer with single-molecule sensitivity and multiplexing. J. Laborat. Autom. (2016) 21: 533– 47. doi: 10.1177/2211068215589580 26077162 · DOI
  162. [172]Naegelin Y Dingsdale H Säuberli K Schädelin S Kappos L Barde Y-A. Measuring and validating the levels of brain-derived neurotrophic factor in human serum. eNeuro. (2018) 5: e419. doi: 10.1523/ENEURO.0419-17.2018 PMC5898630 29662942 · DOI
  163. [173]Nagahara AH Tuszynski MH. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov. (2011) 10: 209– 19. doi: 10.1038/nrd3366 21358740 · DOI · Paper page

Cited by

Sorted by citations

Authors
Maiworm, M.
Affiliations
University Hospital Frankfurt (DE)
Corresponding author
Maiworm, Michelle
ORCID
Maiworm, Michelle
Venue
Frontiers in Neurology
Publisher
Frontiers Media SA
Published
2024-08-01
Volume
15
Pages
1385042-1385042
ISSN
1664-2295 (ISSN-L)
DOI
10.3389/fneur.2024.1385042
PMC
PMC11325594
OpenAlex
W4401217265
Cited by
27
References
9
Citations by year
2026: 10 · 2025: 14 · 2024: 3
FWCI
2.02
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Neurology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) (submittedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Multiple Sclerosis Research Studies
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Spinal Cord Injury Research
Keywords
brain-derived neurotrophic factor, multiple sclerosis, neuroplasticity, neuroprotection, remyelination, BDNF Val66Met polymorphism, neurotrophins, disability, anti-inflammatory activity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review